Author:
Mikhail Mark,Chua Kevin J.,Khizir Labeeqa,Tabakin Alexandra,Singer Eric A.
Abstract
Treatment of metastatic renal cell carcinoma (mRCC) has evolved with the development of a variety of systemic agents; however, these therapies alone rarely lead to a complete response. Complete consolidative surgery with surgical metastasectomy has been associated with improved survival outcomes in well-selected patients in previous reports. No randomized control trial exists to determine the effectiveness of metastasectomy. Therefore, reviewing observational studies is important to best determine which patients are most appropriate for metastasectomy for mRCC and if such treatment continues to be effective with the development of new systemic therapies such as immunotherapy. In this narrative review, we discuss the indications for metastasectomies, outcomes, factors associated with improved survival, and special considerations such as location of metastasis, number of metastases, synchronous metastases, and use of systemic therapy. Additionally, alternative treatment options and trials involving metastasectomy will be reviewed.
Funder
grant from the National Cancer Institute
Reference145 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Clearing up clear cell: clarifying the immuno-oncology treatment landscape for metastatic clear cell RCC;Doppalapudi;Cancers (Basel),2021
3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
4. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors;Motzer;Cancer,2010
5. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med. May,2007
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献